Cardiol Therapeutics (CRDL) Receivables (2020 - 2026)

Cardiol Therapeutics has reported Receivables for 7 years, with the latest figure at -$21209.7 in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 303.83% year-over-year to -$21209.7; the trailing twelve-month figure through Mar 2026 stood at -$21209.7 (down 303.83% YoY), and the FY2025 full-year result was $162201.3, down 37.34% from the prior year.
• Receivables for Q1 2026 stood at -$21209.7, down from $162201.3 in the prior quarter.
• The five-year high for Receivables was $353762.5 in Q4 2022, with the low at -$62269.1 in Q1 2022.
• Historically, Receivables has averaged $84895.6 across 5 years, with a median of $53283.3 in 2023.
• Annual changes were most pronounced in 2023 — Receivables jumped 4643.77% — and 2026, when it tumbled 303.83%.
• Cardiol Therapeutics' Receivables stood at $353762.5 in 2022, then tumbled by 41.89% to $205575.9 in 2023, then rose by 25.92% to $258866.1 in 2024, then sank by 37.34% to $162201.3 in 2025, then tumbled by 113.08% to -$21209.7 in 2026.
• The last three Receivables figures came in at -$21209.7 (Q1 2026), $162201.3 (Q4 2025), and $160773.8 (Q3 2025), per Business Quant data.